validated biomarkers
anti-cancer agents
anti-cancer drugs
feasibility project
novel predictive drug response biomarkers
cancer cell line profiling
leukemia patients
addition
overall improvement of cancer therapy
commercialization phase
increased clinical availability of genomic biomarkers
miniaturized proliferation assays
mutant status of cancer genes
genomic drug sensitivity markers
Clinical validation of prognostic biomarkers of chemotherapy response
T-cell leukemia
novel IP
corresponding agents
successful completion of Phase
diagnostic companies
years
genome sequencing data of patients
poor response rates
characterized cell lines
blood samples
optimal treatment
protein kinase
patient blood cells
increased sustainability of health care systems
circulating DNA
liquid biopsies
researchers
lack
glucocorticoid resistance
proprietary inhibitors
value of NTRCâ€™s biomarker discovery platform
high societal costs
broad panel
study
ROI
times
major problem
initial investment
doubling of turn
results